--- title: "Daily Hong Kong Stock Market News Briefing (January 23, Thursday)" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/225911937.md" description: "Daily Hong Kong Stock Market News Brief: 1. The State Council Information Office emphasized promoting medium- and long-term funds to enter the market and facilitating the high-quality development of the capital market. 2. FOSUN PHARMA announced that the merger and privatization agreement with HENLIUS has not been reached, retaining its H-share listing status. 3. China National Offshore Oil Corporation announced its operational strategy for 2025, with a daily net production target exceeding 2 million barrels. 4. China Metallurgical Group's new contract amount for 2024 decreased by 12.4%. 5. JS Global Life expects a profit of no less than USD 8.1 million for the fiscal year 2024. 6. Harbin Electric expects an annual net profit attributable to the parent company of 1.7 billion yuan. 7. China Pacific Insurance expects a net profit attributable to the parent company of 42.2 billion to 46.3 billion yuan for 2024. 8. Luoyang Molybdenum expects a net profit attributable to the parent company of 12.8 billion to 14.2 billion yuan for 2024. 9. Chow Tai Fook's retail value in the third quarter decreased by 14.2% year-on-year" datetime: "2025-01-23T01:02:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/225911937.md) - [en](https://longbridge.com/en/news/225911937.md) - [zh-HK](https://longbridge.com/zh-HK/news/225911937.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/225911937.md) | [English](https://longbridge.com/en/news/225911937.md) # Daily Hong Kong Stock Market News Briefing (January 23, Thursday) Important News 1. The State Council Information Office held a press conference on vigorously promoting the entry of medium- and long-term funds into the market and promoting the high-quality development of the capital market. Individual Stock News 2. FOSUN PHARMA (02196.HK): The conditions for the effectiveness of the merger and privatization agreement for its holding subsidiary HENLIUS have not been met, and the merger will not be implemented. HENLIUS will retain its H-share listing status. 3. China National Offshore Oil Corporation (00883.HK) announced its operational strategy and development plan for 2025, with a daily net production target of over 2 million barrels of oil equivalent/day in 2025, and a full-year dividend payout ratio of no less than 45% from 2025 to 2027. 4. China Metallurgical Group Corporation (01618.HK) announced that the new contract amount signed by the company in 2024 is RMB 1,248.3 billion, a decrease of 12.4% year-on-year, with the new contract amount in the fourth quarter being RMB 356.61 billion, a decrease of 19.5% year-on-year. 5. JS Global Life (01691.HK) announced that it expects the group's profit from continuing operations for the fiscal year 2024 to be no less than USD 8.1 million (for the year ending December 31, 2023: USD 70.3 million), a decrease of no more than 88.5% compared to the same period last year. 6. Shanghai Pharmaceuticals (02607.HK): The company's holding subsidiary Changzhou Pharmaceutical Factory Co., Ltd. has received approval to produce ursodeoxycholic acid capsules. 7. Harbin Electric (01133.HK): It is expected that the annual net profit attributable to the parent company will be approximately RMB 1.7 billion (approximately RMB 575 million in the same period last year), a significant increase compared to the same period last year. 8. China Pacific Insurance (02601.HK): It is expected that the net profit attributable to the parent company for 2024 will be approximately RMB 42.2 billion to RMB 46.3 billion, an increase of about 55% to 70% year-on-year. 9. Luoyang Molybdenum (03993.HK): It is expected that the net profit attributable to the parent company for 2024 will be RMB 12.8 billion to RMB 14.2 billion, an increase of 55.15%-72.12% year-on-year. 10. Chow Tai Fook (01929.HK): The retail value for the third quarter ending December 31, 2024, decreased by 14.2% year-on-year ### 相關股票 - [FOSUN PHARMA (600196.CN)](https://longbridge.com/zh-HK/quote/600196.CN.md) - [FOSUN PHARMA (02196.HK)](https://longbridge.com/zh-HK/quote/02196.HK.md) - [HENLIUS (02696.HK)](https://longbridge.com/zh-HK/quote/02696.HK.md) - [CPIC (02601.HK)](https://longbridge.com/zh-HK/quote/02601.HK.md) - [JS GLOBAL LIFE (01691.HK)](https://longbridge.com/zh-HK/quote/01691.HK.md) - [HARBIN ELECTRIC (01133.HK)](https://longbridge.com/zh-HK/quote/01133.HK.md) - [FOSUN INTL (00656.HK)](https://longbridge.com/zh-HK/quote/00656.HK.md) - [TOPSPORTS (06110.HK)](https://longbridge.com/zh-HK/quote/06110.HK.md) - [CHOW TAI FOOK (01929.HK)](https://longbridge.com/zh-HK/quote/01929.HK.md) - [MCC (01618.HK)](https://longbridge.com/zh-HK/quote/01618.HK.md) - [SH PHARMA (02607.HK)](https://longbridge.com/zh-HK/quote/02607.HK.md) - [PING AN HKDIV (03070.HK)](https://longbridge.com/zh-HK/quote/03070.HK.md) - [PAB (000001.CN)](https://longbridge.com/zh-HK/quote/000001.CN.md) - [CNOOC (00883.HK)](https://longbridge.com/zh-HK/quote/00883.HK.md) - [CMOC (03993.HK)](https://longbridge.com/zh-HK/quote/03993.HK.md) ## 相關資訊與研究 - [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-HK/news/280997570.md) - [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/zh-HK/news/281035263.md) - [Starfighters Space Delays Annual 10-K Filing](https://longbridge.com/zh-HK/news/281397627.md) - [Styland Subsidiary Commits US$3.4 Million to Alpha Perpetual Income Fund](https://longbridge.com/zh-HK/news/281380835.md) - [In pursuit of profit, India Inc slows R&D as innovation takes back seat](https://longbridge.com/zh-HK/news/281098039.md)